FGEN Projected Dividend Yield
FibroGen Inc ( NASDAQ : FGEN )FibroGen is a biopharmaceutical company that developes and commercializes a pipeline of therapeutics. Co. applies its capability in hypoxia-inducible factor (HIF) biology and connective tissue growth factor (CTGF) biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, Co.'s main product, is an inhibitor of HIF-prolyl hydroxylase activity that acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. Pamrevlumab is Co.'s human monoclonal antibody that inhibits the activity of CTGF for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, and Duchenne muscular dystroph. 20 YEAR PERFORMANCE RESULTS |
FGEN Dividend History Detail FGEN Dividend News FGEN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |